These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12001908)

  • 1. Expression of survival receptors in Hodgkin disease cell lines.
    Bosshart H
    Blood; 2002 May; 99(9):3484-5; author reply 3485-6. PubMed ID: 12001908
    [No Abstract]   [Full Text] [Related]  

  • 2. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines.
    Fiumara P; Snell V; Li Y; Mukhopadhyay A; Younes M; Gillenwater AM; Cabanillas F; Aggarwal BB; Younes A
    Blood; 2001 Nov; 98(9):2784-90. PubMed ID: 11675352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
    Van Poznak C; Cross SS; Saggese M; Hudis C; Panageas KS; Norton L; Coleman RE; Holen I
    J Clin Pathol; 2006 Jan; 59(1):56-63. PubMed ID: 16394281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells.
    Secchiero P; Corallini F; Barbarotto E; Melloni E; di Iasio MG; Tiribelli M; Zauli G
    J Cell Physiol; 2006 Apr; 207(1):158-64. PubMed ID: 16270354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of bone-regulating factors osteoprotegerin (OPG) and receptor activator of NF-kappaB ligand (RANKL) in heterotopic vascular ossification.
    Al-Fakhri N; Hofbauer LC; Preissner KT; Franke FE; Schoppet M
    Thromb Haemost; 2005 Dec; 94(6):1335-7. PubMed ID: 16411417
    [No Abstract]   [Full Text] [Related]  

  • 6. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
    Shipman CM; Croucher PI
    Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RANK ligand and osteoprotegerin: emerging roles in mucosal inflammation.
    Ashcroft AJ; Carding SR
    Gut; 2005 Sep; 54(9):1345-6. PubMed ID: 16099805
    [No Abstract]   [Full Text] [Related]  

  • 8. Regulation of RANKL might reduce bone metastases .
    Burton A
    Lancet Oncol; 2006 May; 7(5):367. PubMed ID: 16696160
    [No Abstract]   [Full Text] [Related]  

  • 9. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification.
    Kaden JJ; Bickelhaupt S; Grobholz R; Haase KK; Sarikoç A; Kiliç R; Brueckmann M; Lang S; Zahn I; Vahl C; Hagl S; Dempfle CE; Borggrefe M
    J Mol Cell Cardiol; 2004 Jan; 36(1):57-66. PubMed ID: 14734048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of receptor activator of nuclear factor kappa B (RANK), its ligand (RANK-L) and osteoprotegerin (OPG) in bone metabolism].
    Stajszczyk M
    Pol Arch Med Wewn; 2002 Sep; 108(3):915-24. PubMed ID: 12600190
    [No Abstract]   [Full Text] [Related]  

  • 11. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
    Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
    J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RANKL inhibitors: a bright future?
    Roux S
    Joint Bone Spine; 2006 Mar; 73(2):129-31. PubMed ID: 16488648
    [No Abstract]   [Full Text] [Related]  

  • 13. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation.
    Chen G; Sircar K; Aprikian A; Potti A; Goltzman D; Rabbani SA
    Cancer; 2006 Jul; 107(2):289-98. PubMed ID: 16752412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand.
    Lee CK; Lee EY; Chung SM; Mun SH; Yoo B; Moon HB
    Arthritis Rheum; 2004 Dec; 50(12):3831-43. PubMed ID: 15593184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-lived immature dendritic cells mediated by TRANCE-RANK interaction.
    Cremer I; Dieu-Nosjean MC; Maréchal S; Dezutter-Dambuyant C; Goddard S; Adams D; Winter N; Menetrier-Caux C; Sautès-Fridman C; Fridman WH; Mueller CG
    Blood; 2002 Nov; 100(10):3646-55. PubMed ID: 12393586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple myeloma.
    Schneider HG; Sentry J
    N Engl J Med; 2005 Feb; 352(8):840-1; author reply 840-1. PubMed ID: 15736296
    [No Abstract]   [Full Text] [Related]  

  • 17. Unbalanced RANKL/RANK pathway in aortic valve sclerosis.
    Mallat Z; Tedgui A
    J Mol Cell Cardiol; 2004 Jan; 36(1):17-9. PubMed ID: 14734042
    [No Abstract]   [Full Text] [Related]  

  • 18. Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3.
    Voskaridou E; Terpos E
    Eur J Haematol; 2005 Apr; 74(4):359-61. PubMed ID: 15777350
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.
    Hofbauer LC; Heufelder AE
    J Mol Med (Berl); 2001 Jun; 79(5-6):243-53. PubMed ID: 11485016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer.
    Li Y; Kucuk O; Hussain M; Abrams J; Cher ML; Sarkar FH
    Cancer Res; 2006 May; 66(9):4816-25. PubMed ID: 16651437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.